Odile Launay

Summary

Country: France

Publications

  1. ncbi [Antiretroviral therapy: principles for treating HIV infection]
    Odile Launay
    CIC de vaccinologie Cochin Pasteur, Pôle de médecine, AP HP, Groupe Hospitalier Cochin Saint Vincent De Paul, F 75014 Paris, France
    Presse Med 37:1022-32. 2008
  2. ncbi Hepatitis C virus-specific cellular immune responses in individuals with no evidence of infection
    Yves Riviere
    Laboratoire d Immunopathologie Virale, Institut Pasteur and CNRS URA 3015, 25 rue du Dr Roux, 75015 Paris, France
    Virol J 9:76. 2012
  3. ncbi Cellular immune responses induced with dose-sparing intradermal administration of HIV vaccine to HIV-uninfected volunteers in the ANRS VAC16 trial
    Odile Launay
    Universite Paris Descartes, Faculte de Medecine, Paris, France
    PLoS ONE 2:e725. 2007
  4. ncbi Immunological efficacy of a three-dose schedule of hepatitis A vaccine in HIV-infected adults: HEPAVAC study
    Odile Launay
    Universite Paris Descartes, Faculte de Medecine, Paris, France
    J Acquir Immune Defic Syndr 49:272-5. 2008
  5. ncbi Vaccines: specific features, simulation of impact and medico-economic modelling
    Odile Launay
    Universite Paris Descartes, AP HP, INSERM, CIC de vaccinologie Cochin Pasteur, Paris, France
    Therapie 65:357-65, 347-55. 2010
  6. ncbi Safety and immunogenicity of 4 intramuscular double doses and 4 intradermal low doses vs standard hepatitis B vaccine regimen in adults with HIV-1: a randomized controlled trial
    Odile Launay
    Paris Descartes University, France
    JAMA 305:1432-40. 2011
  7. ncbi Safety and immunogenicity of a monovalent 2009 influenza A/H1N1v vaccine adjuvanted with AS03A or unadjuvanted in HIV-infected adults: a randomized, controlled trial
    Odile Launay
    Universite Paris Descartes, France
    J Infect Dis 204:124-34. 2011
  8. ncbi Residual HIV-1 RNA and HIV-1 DNA production in the genital tract reservoir of women treated with HAART: the prospective ANRS EP24 GYNODYN study
    Odile Launay
    Faculté de Médecine Paris Descartes, Universite Paris Descartes, Paris, France
    Antivir Ther 16:843-52. 2011
  9. ncbi [Avian influenza: vaccines and vaccine politics]
    O Launay
    CIC de vaccinologie Cochin Pasteur et AP-HP, Groupe Hospitalier Cochin Saint Vincent De Paul, , 27 rue du Faubourg Saint-Jacques, Paris, France
    Rev Mal Respir 25:502-3. 2008
  10. ncbi Contribution of cellular HIV-1 DNA quantification to the efficacy analysis of antiretroviral therapy: a randomized comparison of 2 regimens, including 3 drugs from 2 or 3 classes (TRIANON, ANRS 081)
    Laurence Morand-Joubert
    Saint Antoine Hospital, AP HP, Universite Paris VI, Paris, France
    J Acquir Immune Defic Syndr 38:268-76. 2005

Detail Information

Publications88

  1. ncbi [Antiretroviral therapy: principles for treating HIV infection]
    Odile Launay
    CIC de vaccinologie Cochin Pasteur, Pôle de médecine, AP HP, Groupe Hospitalier Cochin Saint Vincent De Paul, F 75014 Paris, France
    Presse Med 37:1022-32. 2008
    ..It is thus essential to continue developing new drugs and assessing new strategies for their use...
  2. ncbi Hepatitis C virus-specific cellular immune responses in individuals with no evidence of infection
    Yves Riviere
    Laboratoire d Immunopathologie Virale, Institut Pasteur and CNRS URA 3015, 25 rue du Dr Roux, 75015 Paris, France
    Virol J 9:76. 2012
    ..This result would be consistent with unapparent primary HCV infections that either cleared spontaneously or remained undetected by conventional serological assays...
  3. ncbi Cellular immune responses induced with dose-sparing intradermal administration of HIV vaccine to HIV-uninfected volunteers in the ANRS VAC16 trial
    Odile Launay
    Universite Paris Descartes, Faculte de Medecine, Paris, France
    PLoS ONE 2:e725. 2007
    ..The objective was to compare the safety and cellular immunogenicity of intradermal versus intramuscular immunization with an HIV-lipopeptide candidate vaccine (LIPO-4) in healthy volunteers...
  4. ncbi Immunological efficacy of a three-dose schedule of hepatitis A vaccine in HIV-infected adults: HEPAVAC study
    Odile Launay
    Universite Paris Descartes, Faculte de Medecine, Paris, France
    J Acquir Immune Defic Syndr 49:272-5. 2008
    ..The immunogenicity of vaccines, including vaccine against hepatitis A virus (HAV), is impaired in patients with HIV infection, requiring revised immunization regimens...
  5. ncbi Vaccines: specific features, simulation of impact and medico-economic modelling
    Odile Launay
    Universite Paris Descartes, AP HP, INSERM, CIC de vaccinologie Cochin Pasteur, Paris, France
    Therapie 65:357-65, 347-55. 2010
    ..The Round Table has also proposed the creation of a working group to be responsible for pursuing, monitoring and implementing the proposals formulated...
  6. ncbi Safety and immunogenicity of 4 intramuscular double doses and 4 intradermal low doses vs standard hepatitis B vaccine regimen in adults with HIV-1: a randomized controlled trial
    Odile Launay
    Paris Descartes University, France
    JAMA 305:1432-40. 2011
    ..Alternative schedules more immunogenic than the standard hepatitis B vaccine regimen are needed in patients with human immunodeficiency virus 1 (HIV-1) infection...
  7. ncbi Safety and immunogenicity of a monovalent 2009 influenza A/H1N1v vaccine adjuvanted with AS03A or unadjuvanted in HIV-infected adults: a randomized, controlled trial
    Odile Launay
    Universite Paris Descartes, France
    J Infect Dis 204:124-34. 2011
    ..Human immunodeficiency virus (HIV)-infected patients have decreased immune response to vaccines. Few data are available about pandemic flu vaccination in this population...
  8. ncbi Residual HIV-1 RNA and HIV-1 DNA production in the genital tract reservoir of women treated with HAART: the prospective ANRS EP24 GYNODYN study
    Odile Launay
    Faculté de Médecine Paris Descartes, Universite Paris Descartes, Paris, France
    Antivir Ther 16:843-52. 2011
    ..The objective of this study was to prospectively assess residual HIV-1 RNA and HIV-1 DNA production in the genital tract reservoir of women initiating HAART over an 18-month period...
  9. ncbi [Avian influenza: vaccines and vaccine politics]
    O Launay
    CIC de vaccinologie Cochin Pasteur et AP-HP, Groupe Hospitalier Cochin Saint Vincent De Paul, , 27 rue du Faubourg Saint-Jacques, Paris, France
    Rev Mal Respir 25:502-3. 2008
  10. ncbi Contribution of cellular HIV-1 DNA quantification to the efficacy analysis of antiretroviral therapy: a randomized comparison of 2 regimens, including 3 drugs from 2 or 3 classes (TRIANON, ANRS 081)
    Laurence Morand-Joubert
    Saint Antoine Hospital, AP HP, Universite Paris VI, Paris, France
    J Acquir Immune Defic Syndr 38:268-76. 2005
    ..In conclusion, the changes under therapy in cellular HIV-1 DNA level, which were mostly coincident to those of plasma HIV-1 RNA, did not add significant information to the comparison of the viral efficacy of the 2 studied regimens...
  11. ncbi Lamivudine and indinavir/ritonavir maintenance therapy in highly pretreated HIV-infected patients (Vista ANRS 109)
    Odile Launay
    , , Service de Medecine Interne, Hopital Cochin, AP-HP, Paris, France
    Antivir Ther 11:889-99. 2006
    ..CONCLUSIONS: In patients with advanced resistance, treatment simplification prevented resurgence of wild-type HIV, reduced drug burden, but failed to stabilize progression of the immune deficiency...
  12. ncbi Pregnancy outcomes in women with HIV type-1 receiving a lopinavir/ritonavir-containing regimen
    Elie Azria
    Universite Paris Descartes, Faculte de Medecine, Paris, France
    Antivir Ther 14:423-32. 2009
    ..The objective of our study was to explore whether lopinavir/ritonavir (LPV/r) exposure during pregnancy is associated with adverse outcomes...
  13. ncbi Immunogenicity and safety of seasonal and 2009 pandemic A/H1N1 influenza vaccines for patients with autoimmune diseases: a prospective, monocentre trial on 199 patients
    Alex Kostianovsky
    Department of Internal Medicine, Hopital Cochin, Assistance Publique Hopitaux de Paris, Universite Paris Descartes, Sorbonne Paris Cité, INSERM U1060, Referral Center for Rare Autoimmune Systemic Diseases, Paris, France
    Clin Exp Rheumatol 30:S83-9. 2012
    ..This study was undertaken to evaluate immunogenicity and tolerance of seasonal (SFV) and A/H1N1 flu vaccines (HFV) in AID patients...
  14. ncbi Pregnancy-related effects on tenofovir pharmacokinetics: a population study with 186 women
    Sihem Benaboud
    Université Paris Descartes Sorbonne Paris Cité, EA3620, Paris, France
    Antimicrob Agents Chemother 56:857-62. 2012
    ....
  15. ncbi Effect of sublingual administration of interferon-alpha on the immune response to influenza vaccination in institutionalized elderly individuals
    Odile Launay
    Universite Paris Descartes, Faculte de Medecine, Paris, France
    Vaccine 26:4073-9. 2008
    ..At the dose tested sublingual administration of IFNalpha reduces the immune response to influenza vaccination in elderly institutionalized individuals...
  16. ncbi Population analysis of the pregnancy-related modifications in lopinavir pharmacokinetics and their possible consequences for dose adjustment
    Marion Bouillon-Pichault
    Universite Paris Descartes, France
    J Antimicrob Chemother 63:1223-32. 2009
    ..To investigate the possible necessity of an increase in lopinavir dose during pregnancy in order to achieve the concentrations previously defined as predictive of virological efficacy...
  17. ncbi Immunogenicity and safety of an HIV-1 lipopeptide vaccine in healthy adults: a phase 2 placebo-controlled ANRS trial
    Dominique Salmon-Ceron
    Universite Paris Descartes, Assistance Publique Hopitaux de Paris, Hopital Cochin, France
    AIDS 24:2211-23. 2010
    ..Whether HIV-LIPO-5 immunogenicity varies with the dose is unknown...
  18. ncbi Patients with systemic inflammatory and autoimmune diseases are at risk of vaccine-preventable illnesses
    Cecile Marchand-Janssen
    Universite Paris Descartes, Faculte de Medecine, INSERM, CIC BT505, Assistance Publique Hopitaux de Paris, Groupe Hospitalier Cochin Saint Vincent De Paul, Pôle de médecine, CIC de vaccinologie Cochin Pasteur, Paris, France
    Rheumatology (Oxford) 50:1099-105. 2011
    ..To evaluate vaccine coverage and humoral immunity to tetanus, diphtheria and poliomyelitis in adults followed for systemic inflammatory and/or autoimmune diseases (SIADs)...
  19. ncbi A cohort study of enfuvirtide immunological and virological efficacy in clinical practice
    Boris Bienvenu
    , , Paris, France
    J Med Virol 78:1312-7. 2006
    ..However, the mutations conferring resistance to enfuvirtide develop rapidly when viral load is not controlled confirming that enfuvirtide should be prescribed in association with an active background regimen...
  20. ncbi Flexibility of interval between vaccinations with AS03A-adjuvanted influenza A (H1N1) 2009 vaccine in adults aged 18-60 and >60 years: a randomized trial
    Xavier Duval
    Universite Paris Diderot, Sorbonne Paris Cité, Paris, UMR 738, France
    BMC Infect Dis 12:162. 2012
    ....
  21. ncbi Pregnancy-related effects on lamivudine pharmacokinetics in a population study with 228 women
    Sihem Benaboud
    Universite Paris Descartes, Paris, France
    Antimicrob Agents Chemother 56:776-82. 2012
    ..9. Pregnant women had a 22% higher apparent clearance than nonpregnant and parturient women; however, this increase did not lead to subexposure and should not require a dosage adjustment...
  22. ncbi [Pregnancy: a high risk factor in influenza infection]
    Caroline Charlier
    Universite Paris Descartes, Service de Maladies Infectieuses et Tropicales, Centre d Infectiologie Necker Pasteur, Hopital Necker Enfants Malades, Groupe infections de la mère et de l enfant, Assistance Publique Hopitaux de Paris, 149, rue de Sevres, 75015 Paris, France
    Med Sci (Paris) 26:100-4. 2010
    ..We also provide an update on the epidemiological data available for the A/H1N1v infection in this population, and discuss the benefit/risk ratio of treatment with the antiviral medications...
  23. ncbi Gag mutations strongly contribute to HIV-1 resistance to protease inhibitors in highly drug-experienced patients besides compensating for fitness loss
    Elisabeth Dam
    INSERM U552, Paris, France
    PLoS Pathog 5:e1000345. 2009
    ..Further compensatory mutations render viral RC independent of the A431V or I437V mutations while their effect on resistance persists...
  24. ncbi A population analysis of weight-related differences in lopinavir pharmacokinetics and possible consequences for protease inhibitor-naive and -experienced patients
    Marion Bouillon-Pichault
    Universite Paris Descartes, Paris, France
    Antivir Ther 14:923-9. 2009
    ..However, the probability to achieve these target C(troughs) with the current 400 mg twice-daily or 800 mg once-daily doses of the new tablet form, and the influence of body weight on this probability are unknown...
  25. ncbi [Flu vaccine and auto-immune and/or inflammatory diseases]
    Paula Duchet-Niedziolka
    Universite Paris Descartes, Assistance Publique Hopitaux de Paris AP HP, Hopital Cochin, Centre d Investigation Clinique de Vaccinologie Cochin Pasteur, INSERM, CIC BT505, Paris, France
    Presse Med 40:248-52. 2011
    ..More data are needed about the severity of influenza infection and the efficacy of influenza vaccination in patients with systemic inflammatory and/or autoimmune diseases to improve their vaccine coverage...
  26. ncbi Low Rate of Pandemic A/H1N1 2009 Influenza Infection and Lack of Severe Complication of Vaccination in Pregnant Women: A Prospective Cohort Study
    Odile Launay
    Universite Paris Descartes, Paris, France INSERM, CIC BT505, Paris, France Assistance Publique Hôpitaux de Paris AP HP, Hopital Cochin, CIC de vaccinologie Cochin Pasteur, Paris, France
    PLoS ONE 7:e52303. 2012
    ..The objectives of the COFLUPREG study, initially set up to assess the incidence of serious forms of A/H1N1 influenza, were to assess the consequences of maternal vaccination on pregnancy outcomes and maternal seroprotection at delivery...
  27. ncbi Vaccination against viral hepatitis of HIV-1 infected patients
    Bao Chau Phung
    Universite Paris Descartes, Faculte de Medicine, Assistance Publique Hopitaux de Paris, Hopital Cochin, CIC de vaccinologie Cochin Pasteur, INSERM, CIC BT505, Paris, France
    Hum Vaccin Immunother 8:554-9. 2012
    ..To assume a higher immune response, vaccines should be administered in HIV-infected patients with undetectable HIV viral load and high CD4 cell count...
  28. ncbi Adherence to preventive measures after splenectomy in the hospital setting and in the community
    Hélène Coignard-Biehler
    Paris Descartes University, Paris, France
    J Infect Public Health 4:187-94. 2011
    ..Overwhelming post-splenectomy infection (OPSI) remains a long-term risk in asplenic patients, which may be reduced by appropriate preventive measures. Specific guidelines have been developed to lower its incidence...
  29. ncbi Short communication: Long-term persistence of vaccine-induced HIV seropositivity among healthy volunteers
    Benjamin Silbermann
    AP HP, Groupe Hospitalier Cochin Saint Vincent De Paul, CIC de vaccinologie Cochin Pasteur, Pôle de médecine, Paris, France
    AIDS Res Hum Retroviruses 24:1445-8. 2008
    ..Because rgp160 induces long-term persistence (>8 years) of vaccine-induced HIV seropositivity, volunteers should be offered long-term follow-up to monitor their serological evolution...
  30. ncbi [Pneumococcal infections and vaccination in patients with systemic autoimmune and/or inflammatory diseases]
    Paula Duchet-Niedziolka
    Centre d Investigation Clinique de Vaccinologie Cochin Pasteur, Pôle de médecine, Groupe Hospitalier Cochin Saint Vincent De Paul, Assistance Publique Hopitaux de Paris, Paris Cedex 14, France
    Presse Med 38:243-50. 2009
    ..More immunogenic vaccine strategy should be evaluated in patients with systemic autoimmune and/or inflammatory diseases to provide better vaccine coverage...
  31. ncbi [Measles and pregnancy]
    Olivia Anselem
    Faculte de Medecine, Universite Paris Descartes, Paris, France
    Presse Med 40:1001-7. 2011
    ..Measles vaccine, an attenuated living vaccine, should not be administered during pregnancy but must be proposed before pregnancy or during the post-partum period...
  32. ncbi Term labor management and outcomes in treated HIV-infected women without contraindications to vaginal delivery and matched controls
    Elie Azria
    Assistance Publique Hopitaux de Paris, Département de Gynécologie et d Obstétrique, Groupe Hospitalier Bichat Claude Bernard, Paris, France
    Int J Gynaecol Obstet 111:161-4. 2010
    ..To assess labor management and outcomes for treated HIV-infected pregnant women with no obstetric or virologic contraindications to vaginal delivery...
  33. ncbi [Vaccination in patients with cirrhosis]
    Pierre Loulergue
    Universite Paris Descartes, Faculte de Medecine, INSERM CIC BT 505, AP HP, Groupe Hospitalier Cochin Saint Vincent De Paul, CIC de vaccinologie Cochin Pasteur, Pôle de médecine, F 75679, Paris Cedex 14, France
    Presse Med 38:1134-40. 2009
    ..Few data regarding vaccination coverage are available, but studies suggest that immunization rates are too low in this population...
  34. ncbi Why actively promote vaccination in patients with cirrhosis?
    Pierre Loulergue
    Universite Paris Descartes, Faculte de Medecine, Paris, France
    J Clin Virol 46:206-9. 2009
    ..Few data regarding vaccination coverage are available, but studies suggest that immunization rates are too low in this population...
  35. ncbi Predictive values of the human immunodeficiency virus phenotype and genotype and of amprenavir and lopinavir inhibitory quotients in heavily pretreated patients on a ritonavir-boosted dual-protease-inhibitor regimen
    Aurélie Barrail-Tran
    Assistance Publique Hopitaux de Paris, Hopital Bicetre, Service de Pharmacie Clinique, Paris, France
    Antimicrob Agents Chemother 52:1642-6. 2008
    ..High amprenavir and lopinavir concentrations in these patients might explain why plasma concentrations and the phenotypic IQ have poor predictive value...
  36. ncbi Humoral immunity of dTap-IPV vaccine (REPEVAX®) administered one month after dT-IPV vaccine (REVAXIS®) in adults with unknown vaccination history
    Sylvie Larnaudie
    DASES, Service des vaccinations, Paris, France
    Hum Vaccin 6:829-34. 2010
    ..These results validate a vaccination schedule routinely used for years that rapidly elicits effective immunization against diphtheria, tetanus, poliomyelitis and pertussis...
  37. ncbi Nevirapine or lamivudine plus stavudine and indinavir: examples of 2-class versus 3-class regimens for the treatment of human immunodeficiency virus type 1
    Odile Launay
    Service de Maladies Infectieuses et Tropicales, Hopital Bichat Claude Bernard, Paris, France
    Clin Infect Dis 35:1096-105. 2002
    ..These results do not support the use of a 3-class regimen that includes Nvp for patients with no or limited exposure to nucleoside analogues...
  38. ncbi [Vaccination in patients with systemic diseases]
    Thomas Hanslik
    Service de Medecine Interne, Hopital Ambroise Pare, Assistance Publique Hopitaux de Paris, Universite de Versailles Saint Quentin en Yvelines, Boulogne Billancourt Cedex, France
    Presse Med 38:235-42. 2009
    ..These findings are an encouragement to properly immunize patients with systemic diseases. Measures should be taken to improve immunization coverage for these patients and their entourage...
  39. ncbi Low influenza vaccination rate among patients with systemic sclerosis
    Luc Mouthon
    Department of Internal Medicine, Cochin Hospital, Paris Cedex 14, France
    Rheumatology (Oxford) 49:600-6. 2010
    ..To evaluate the influenza vaccination rate and factors influencing it in patients with SSc...
  40. ncbi Phase I study of a candidate vaccine based on recombinant HIV-1 gp160 (MN/LAI) administered by the mucosal route to HIV-seronegative volunteers: the ANRS VAC14 study
    Gilles Pialoux
    APHP, Hopital Tenon, 4 rue de la Chine, Paris Cedex 20, France
    Vaccine 26:2657-66. 2008
    ..No anti-gp160 activity was found between week 4 and week 48 in serum, saliva, or cervicovaginal and nasal secretions. These results show that a mucosal HIV vaccine can be well tolerated when administered by the nasal or vaginal route...
  41. ncbi Report of the 2nd "French Clinical Vaccinology Meeting Jean-Gerard Guillet": immunization and respiratory diseases
    P Loulergue
    Universite Paris Descartes, INSERM CIC BT505, Assistance Publique Hopitaux de Paris AP HP, 27 rue du Faubourg Saint Jacques, 75014 Paris, France
    Vaccine 28:6551-5. 2010
    ..We report on here the key findings of the conference, especially the immunization of the chronic respiratory diseases, the clinical effectiveness of vaccines and the development of new vaccines in pulmonology...
  42. ncbi Does enfuvirtide increase the risk of bacterial pneumonia in patients receiving combination antiretroviral therapy?
    I Kousignian
    INSERM U, Paris, France
    J Antimicrob Chemother 65:138-44. 2010
    ....
  43. ncbi Marked increase in the incidence of invasive anal cancer among HIV-infected patients despite treatment with combination antiretroviral therapy
    Christophe Piketty
    AP HP, Department of Clinical Immunology, Georges Pompidou European Hospital, Rene Descartes University, Paris, France
    AIDS 22:1203-11. 2008
    ..To describe the cases of anal cancer that appeared in the French Hospital Database on HIV between 1992 and 2004 and to study risk factors of anal cancer...
  44. ncbi Stable frequency of HIV-1 transmitted drug resistance in patients at the time of primary infection over 1996-2006 in France
    Marie Laure Chaix
    Université Paris Descartes EA 3620, AP HP, Laboratoire de Virologie, CHU Necker Enfants Malades, Paris, France
    AIDS 23:717-24. 2009
    ....
  45. ncbi HIV-1 DNA for the measurement of the HIV reservoir is predictive of disease progression in seroconverters whatever the mode of result expression is
    Véronique Avettand-Fenoel
    AP HP, CHU Necker Enfants Malades, Laboratoire de Virologie, Paris, France
    J Clin Virol 42:399-404. 2008
    ..Previously, HIV-DNA levels have sometimes been reported by other means: copies/10(6) CD4(+)T cells, reflecting the proportion of infected cells; or copies/mL whole blood, reflecting the global blood reservoir size...
  46. ncbi Causes of the first AIDS-defining illness and subsequent survival before and after the advent of combined antiretroviral therapy
    S Grabar
    Department of Public Health, Cochin Hospital, Paris, France
    HIV Med 9:246-56. 2008
    ....
  47. ncbi [Vaccinations for the traveling adult solid organ transplant recipient (excluding hematopoietic stem cell transplant recipients)]
    B Wyplosz
    Unité de maladies infectieuses et tropicales, Hôpital Universitaire Paul Brousse, Assistance Publique Hopitaux de Paris, Faculte de Medecine, Universite Paris Sud 11, 12 14, 94804 Villejuif Cedex, France
    Med Mal Infect 39:225-33. 2009
    ..In this comprehensive review, we provide vaccination schedules based on published studies and guidelines for vaccination of solid organ transplant recipients...
  48. ncbi Incidence of cancer in children perinatally exposed to nucleoside reverse transcriptase inhibitors
    Valérie Benhammou
    INSERM, U822, Le Kremlin Bicetre, France
    AIDS 22:2165-77. 2008
    ..Long-term studies of tolerance to perinatal exposure to antiretroviral nucleoside reverse transcriptase inhibitors are required, in view of the potential genotoxicity of some of these molecules...
  49. ncbi Determinants of non-vaccination against pandemic 2009 H1N1 influenza in pregnant women: a prospective cohort study
    Romain Freund
    INSERM U953, recherche épidémiologique en santé périnatale et santé des femmes et des enfants, Universite Pierre et Marie Curie, Paris, France
    PLoS ONE 6:e20900. 2011
    ..The study objective was to evaluate pandemic flu vaccine uptake and factors associated with non-vaccination in a population of pregnant women...
  50. ncbi Failure of the vaccination campaign against A(H1N1) influenza in pregnant women in France: results from a national survey
    Beatrice Blondel
    INSERM, UMRS 953, Epidemiological Research Unit on Perinatal and Women s and Children s Health, Paris, France
    Vaccine 30:5661-5. 2012
    ..Our objective was to assess the national vaccination rate among pregnant women and to determine the association of vaccination with maternal characteristics, prenatal care, and pregnancy-related health behaviors...
  51. ncbi Maternal immune response and neonatal seroprotection from a single dose of a monovalent nonadjuvanted 2009 influenza A(H1N1) vaccine: a single-group trial
    Vassilis Tsatsaris
    Universite Paris Descartes, Paris, France
    Ann Intern Med 155:733-41. 2011
    ..Pregnant women and infants who get influenza are at increased risk for severe illness...
  52. ncbi [Pandemic and prepandemic H5N1 influenza vaccines: a 2009 update]
    Pierre Loulergue
    Universite Paris Descartes, Faculte de Medecine, INSERM CIC BT505, France
    Med Sci (Paris) 25:719-25. 2009
    ..In 2009, several prepandemic and pandemic vaccines have obtained their licensure authorization and strategies are being developed in case of pandemic influenza...
  53. ncbi [Post-exposure vaccination against hepatitis A]
    Dominique Gendrel
    Groupe Hospitalier Cochin Saint Vincent De Paul, Paris, France
    Therapie 60:221-6. 2005
    ..The availability of this form of protection and active individual prophylaxis should be suggested to families by clinicians...
  54. ncbi Antibodies to tetanus, diphtheria and pertussis among healthy adults vaccinated according to the French vaccination recommendations
    Odile Launay
    Faculte de Medecine, Universite Paris Descartes, Paris, France
    Hum Vaccin 5:341-6. 2009
    ..They also indicate the need for better implementation of the current recommendations for pertussis-vaccine boosters in adults...
  55. ncbi Anti-TNFalpha therapy and vaccination of adults
    Paula Duchet-Niedziolka
    , Groupe Hospitalier Cochin Saint-Vincent de Paul, , Paris, France
    Joint Bone Spine 74:563-5. 2007
  56. ncbi Assessment of cetirizine, an antihistamine, to prevent cutaneous reactions to nevirapine therapy: results of the viramune-zyrtec double-blind, placebo-controlled trial
    O Launay
    Service de Medecine Interne, Hopital Cochin Port Royal Saint Vincent de Paul, AP HP, Paris, France
    Clin Infect Dis 38:e66-72. 2004
    ..83; 95% CI, 1.4-10.46; P=.008) was associated with an increased risk of rash. Cetirizine has no preventive effect on nevirapine-associated rash...
  57. ncbi HIV-2 integrase gene polymorphism and phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitors raltegravir and elvitegravir in vitro
    B Roquebert
    AP HP, Groupe Hospitalier Bichat Claude Bernard, Laboratoire de Virologie, Paris F 75018, France
    J Antimicrob Chemother 62:914-20. 2008
    ..We investigated the in vitro phenotypic susceptibility of HIV-2 isolates from integrase inhibitor (INI)-naive patients to INIs and its relation to HIV-2 integrase gene polymorphism...
  58. ncbi Maternal biochemical serum screening for Down syndrome in pregnancy with human immunodeficiency virus infection
    Jean Patrick Le Meaux
    Assistance Publique Hopitaux de Paris, Groupe Hospitalier Cochin Saint Vincent De Paul, Port Royal Maternity, Paris, France
    Obstet Gynecol 112:223-30. 2008
    ..To estimate the influence of human immunodeficiency virus (HIV) infection and antiretroviral therapy on maternal serum markers levels and the false-positive rate with biochemical maternal serum screening for Down syndrome...
  59. ncbi Cryptococcal neuroradiological lesions correlate with severity during cryptococcal meningoencephalitis in HIV-positive patients in the HAART era
    Caroline Charlier
    Centre National de Référence Mycologie et Antifongiques, Unité de Mycologie Moléculaire, CNRS URA 3012, Institut Pasteur, Paris, France
    PLoS ONE 3:e1950. 2008
    ..Given this, we suggest that investigation for cryptococcosis-related lesions is merited, even in the absence of neurological abnormality, if a high fungal burden is suspected on the basis of high serum and/or CSF antigen titers...
  60. ncbi Influence of environmental factors on disease activity in spondyloarthritis: a prospective cohort study
    Nadine Zeboulon-Ktorza
    From the Ambroise Paré Hospital, APHP, Boulogne Billancourt Versailles Saint Quentin en Yvelines University, Versailles Inserm UMR S 707, Paris UPMC Paris VI University, Paris Saint Antoine Hospital, APHP, Paris Cochin Hospital, APHP, Paris Descartes University, Paris EHESP School of Public Health, Rennes and Inserm U 1016, Paris, France
    J Rheumatol 40:469-75. 2013
    ..Spondyloarthritis (SpA) is a complex inflammatory disorder. We investigated the influence of environmental factors on SpA disease activity...
  61. ncbi Risk of Kaposi sarcoma during the first months on combination antiretroviral therapy
    Jean Marc Lacombe
    Univ Paris 06 UMR S 943, INSERM Transfert, Paris, France
    AIDS 27:635-43. 2013
    ..To determine whether incident AIDS-defining Kaposi sarcoma or Pneumocystis jiroveci pneumonia (PJP) is associated with combination antiretroviral therapy (cART) initiation...
  62. ncbi Long-term immunogenicity of two doses of 2009 A/H1N1v vaccine with and without AS03(A) adjuvant in HIV-1-infected adults
    Christine Durier
    INSERM, SC10, Villejuif, Assistance Publique Hopitaux de Paris AP HP, Hopital Cochin, CIC de vaccinologie Cochin Pasteur, INSERM, CIC BT505, Paris, France
    AIDS 27:87-93. 2013
    ..We previously reported that the AS03A-adjuvanted 2009 A/H1N1v vaccine yielded a higher short-term immune response than the nonadjuvanted one in HIV-1-infected adults. This study reports the long-term persistence of the immune response...
  63. ncbi Neonatal plasmacytoid dendritic cells (pDCs) display subset variation but can elicit potent anti-viral innate responses
    Xiaoming Zhang
    Régulation Immunitaire et Vaccinologie, Institut Pasteur, Paris, France
    PLoS ONE 8:e52003. 2013
    ..Therefore, neonatal pDCs clearly display variation in phenotype and subset composition, but without major consequences for their antiviral responses...
  64. ncbi Immunizations in adult patients with systemic sclerosis
    Odile Launay
    Universite Paris Descartes, Faculte de Medecine, Assistance Publique Hopitaux de Paris, Pôle de médecine, Groupe Hospitalier Cochin Saint Vincent De Paul, CIC de vaccinologie Cochin Pasteur, Institut National de la Sante et de la Recherche Medicale, Paris, France
    Ann N Y Acad Sci 1173:610-8. 2009
    ..In conclusion, there is potential for serious illness and death in the underimmunization of high-risk patients, including those with SSc, and every effort should be made to ensure adequate protection through immunization...
  65. ncbi Susceptibility of health care students to measles, paris, france
    Pierre Loulergue
    Assistance Publique Hopitaux de Paris, Paris, France
    Emerg Infect Dis 17:1766-7. 2011
    ..Although most cases concern unvaccinated children and young adults, health care professionals (HCPs) are also affected. Cases occur mostly in unvaccinated persons, but also in those who have received a single dose of vaccine...
  66. ncbi Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial
    Jean-Louis Bresson
    Centre d'Investigations Cliniques Groupe Hospitalier et Universitaire Necker-Enfants Malades, Paris, France
    Lancet 367:1657-64. 2006
    ..We noted encouraging responses with lower doses of antigen that need further study to ascertain their relevance for the choice of the final pandemic vaccine...
  67. ncbi Determinants of disease presentation and outcome during cryptococcosis: the CryptoA/D study
    Francoise Dromer
    Unité de Mycologie Moléculaire, Centre National de Référence Mycologie et Antifongiques, CNRS URA3042, Institut Pasteur, Paris, France
    PLoS Med 4:e21. 2007
    ....
  68. ncbi On the use of magnitude of reduction in HIV-1 RNA in clinical trials: statistical analysis and potential biases
    Philippe Flandre
    Service Commun 10, INSERM, Villejuif, France
    J Acquir Immune Defic Syndr 30:59-64. 2002
    ....
  69. ncbi Safety and immunogenicity of SC599, an oral live attenuated Shigella dysenteriae type-1 vaccine in healthy volunteers: results of a Phase 2, randomized, double-blind placebo-controlled trial
    Odile Launay
    Universite Paris Descartes, INSERM, Assistance Publique Hopitaux de Paris, CIC de Vaccinologie Cochin Pasteur CIC BT505, Groupe Hospitalier Cochin Saint Vincent De Paul, Paris, France
    Vaccine 27:1184-91. 2009
    ....
  70. ncbi [Preventing papillomavirus infectious and herpes zoster: new vaccines]
    Benjamin Silbermann
    CIC de vaccinologie Cochin Pasteur, Pôle de Médecine Interne, Hopital Cochin 27, rue du Faubourg Saint Jacques, 75014 Paris, France
    Med Sci (Paris) 23:423-7. 2007
    ..Its safety is good among persons 50 years old and over and its efficiency on lowering herpes zoster incidence, on the burden of illness and on post-herpetic neuralgia has been demonstrated in persons over 60 years old...
  71. ncbi Tuberculosis in HIV-infected patients: a comprehensive review
    L Aaron
    Service de Maladies Infectieuses et Tropicales, , Paris, France
    Clin Microbiol Infect 10:388-98. 2004
    ..Finally, immune restoration induced by highly active anti-retroviral therapy (HAART) in developed countries may be responsible for a paradoxical worsening of TB manifestations...
  72. ncbi 2011-12 Seasonal Influenza Vaccines Effectiveness against Confirmed A(H3N2) Influenza Hospitalisation: Pooled Analysis from a European Network of Hospitals. A Pilot Study
    Marc Rondy
    EpiConcept, Paris, France
    PLoS ONE 8:e59681. 2013
    ..We assessed the feasibility of measuring seasonal IVE against hospitalisation with laboratory confirmed influenza through a network of 21 hospitals in the European Union...
  73. ncbi Boosted protease inhibitor monotherapy as a maintenance strategy: an observational study
    Marguerite Guiguet
    INSERM, U, Paris, France
    AIDS 26:2345-50. 2012
    ..We aimed to determine the effectiveness of boosted protease inhibitor monotherapy (BPIMT) initiated as a maintenance strategy in routine care and identify predictive factors of failure...
  74. ncbi [Assisted procreation technology and people with HIV]
    Juliette Guibert
    Service de Gynécologie Obstétrique II, Unité de médecine de la reproduction, AP HP, Hopital Cochin, 75014 Paris, France
    Presse Med 37:998-1006. 2008
    ..Several thousand couples in Europe have used ART without any cases of contamination reported so far. Approximately half of these couples can hope to have a child, but approximately one third decide against ART after consultation...
  75. ncbi Feasibility of azithromycin prophylaxis during a pertussis outbreak among healthcare workers in a university hospital in Paris
    Camila Giugliani
    Service de Sante Publique, Groupe Hospitalier Cochin-St. Vincent de Paul, Paris, France
    Infect Control Hosp Epidemiol 27:626-9. 2006
    ..The rate of adverse events was 33%. Female sex was associated with reporting of adverse events. Nonstudents and healthcare workers who reported adverse events were less compliant with the prophylaxis regimen...
  76. ncbi [Post-licensing surveillance of vaccines]
    Odile Launay
    Service de Medecine Interne, Centre Cochin Pasteur d Essais Vaccinaux, Groupe Hospitalier Cochin Saint Vincent de Paul La Roche Guyon, AP HP, Universite Paris V, Paris, France
    Therapie 60:209-14. 2005
    ..These studies also allow verification of the compatibility between strains contained in the vaccine as well as circulating strains...
  77. ncbi How does loss to follow-up influence cohort findings on HIV infection? A joint analysis of the French hospital database on HIV, Mortalité 2000 survey and death certificates
    E Lanoy
    INSERM, U720, Paris, France
    HIV Med 10:236-45. 2009
    ....
  78. ncbi Cellular CD4 T cell responses to the diphtheria-derived carrier protein of conjugated pneumococcal vaccine and antibody response to pneumococcal vaccination in HIV-infected adults
    Claire Rabian
    Laboratoire d Immunologie et d Histocompatibilité, St Louis Hospital, Paris, France
    Clin Infect Dis 50:1174-83. 2010
    ..CD4 T cell responses specific to the diphtheria-derived carrier protein CRM(197) were evaluated...
  79. ncbi [Antiviral immunization of immunocompromised adults, literature review]
    P Duchet Niedziolka
    CIC de vaccinologie Cochin Pasteur, Pôle de Médecine Interne, Groupe Hospitalier Cochin Saint Vincent De Paul, Assistance Publique Hopitaux de Paris, Universite Rene Descartes Paris 5, 75679 Paris cedex, France
    Rev Med Interne 29:554-67. 2008
    ..In the meantime, a harmonization of immunization practices for immunocompromised adults should be proposed, so as to help practitioners to succeed a better immunization coverage for these patients...
  80. ncbi The changing clinical aspects of infective endocarditis: descriptive review of 90 episodes in a French teaching hospital and risk factors for death
    S Mouly
    Department of Intensive Care and Infectious Diseases, Bichat Claude Bernard Hospital, Paris, France
    J Infect 45:246-56. 2002
    ..We wanted to describe the epidemiological aspects of infective endocarditis (IE) in a French hospital and identify the prognostic factors...
  81. ncbi [Designing an effective AIDS vaccine: strategies and current status]
    Z Coutsinos
    Pôle de médecine, CIC de vaccinologie Cochin Pasteur, Groupe Hospitalier Cochin Saint Vincent De Paul, AP HP, 27, rue du Faubourg Saint Jacques, 75014 Paris, France
    Rev Med Interne 29:632-41. 2008
    ..Moreover, in the absence of a protective vaccine, the impact of a vaccine that confers partial protection needs to be seriously considered...
  82. ncbi Factors influencing influenza-vaccination in adults under immunosuppressive therapy for a systemic inflammatory disease
    F Lanternier
    Pôle de médecine, Groupe Hospitalier Cochin Saint Vincent De Paul, AP HP, Universite Paris Descartes, Paris, France
    Med Mal Infect 39:247-51. 2009
    ..The aim of this study was to evaluate flu vaccination rates and influencing factors in patients with systemic inflammatory diseases...
  83. ncbi Efficacy and tolerability of a nucleoside reverse transcriptase inhibitor-sparing combination of lopinavir/ritonavir and efavirenz in HIV-1-infected patients
    Clotilde Allavena
    Service des Maladies Infectieuses et Tropicales/IFR26, , Nantes, France
    J Acquir Immune Defic Syndr 39:300-6. 2005
    ..CONCLUSION: The lopinavir/ritonavir-efavirenz combination is associated with a high rate of virologic response and should be compared with more classic NRTI-containing regimens in randomized and controlled clinical trials...
  84. ncbi Clinical safety of HIV lipopeptides used as vaccines in healthy volunteers and HIV-infected adults
    Christine Durier
    INSERM SC10, 16 Avenue Paul Caillant Couturier, 94800 Villejuif, France
    AIDS 20:1039-49. 2006
    ..The aim of this study was to review clinical safety of HIV lipopeptides...
  85. ncbi [Prophylaxis for contacts of an index case of hepatitis A: immunoglobulins or vaccination?]
    Dominique Gendrel
    Hopital Cochin Saint Vincent de Paul, Paris, and Centre Hospitalier Universitaire, Clermont Ferrand
    Presse Med 36:1072-7. 2007
    ..This medical decision should thus be made on an individualized basis after discussion between the physician and family about the risk...
  86. ncbi Differential diffusions of indinavir and lopinavir in genital secretions of human immunodeficiency virus-infected women
    Odile Launay
    Fédération de médecine interne, Maladies Infectieuses et Tropicales and UPRES EA 3409, Universite Paris Nord, Bobigny, France
    Antimicrob Agents Chemother 48:632-4. 2004
    ..The relationship between lopinavir and indinavir pharmacodynamics and viral evolution in the female genital tract should be assessed over time...
  87. ncbi Absence of association between MDR1 genetic polymorphisms, indinavir pharmacokinetics and response to highly active antiretroviral therapy
    Celine Verstuyft
    Pharmacology Department, Saint Antoine Hospital, Pierre et Marie Curie University, Paris VI, Assistance Publique Hopitaux de Paris, 37 rue de Chaligny 75012 Paris, France
    AIDS 19:2127-31. 2005
    ..The relationship between MDR1 single nucleotide polymorphisms (SNP) and the pharmacokinetic or pharmacodynamic responses to protease inhibitors has been recently challenged...
  88. ncbi [Epidemiology of HIV-associated malignancies]
    Odile Launay
    Service de Medecine Interne, Universite Paris Nord, Hopital Avicienne, 125, route de Stalingrad, 93009 Bobigny Cedex
    Bull Cancer 90:387-92. 2003
    ..In contrast, the incidence of invasive cervical carcinoma has not changed in the HAART era. The impact of HAART on the epidemiology of other HIV-associated malignancies, including Hodgkin's disease and anal carcinoma, remains unclear...